Сывороточный кальпротектин при иммуновоспалительных ревматических заболеваниях: новый биомаркер воспаления
https://doi.org/10.47360/1995-4484-2025-432-442
Аннотация
При иммуновоспалительных ревматических заболеваниях (ИВРЗ) лабораторные биомаркеры, к которым относятся аутоантитела, белки острой фазы воспаления, цитокины, маркеры повреждения эндотелия, компоненты системы комплемента, субпопуляции лимфоцитов, показатели костного метаболизма и многие другие, занимают центральное место в диагностике, оценке активности и мониторинге эффективности фармакотерапии. В спектре биомаркеров воспаления в последние годы особое внимание привлечено к кальпротектину (КП), представляющему собой гетеродимерный комплекс S100A8 и S100A9 кальций-зависимых белков. В настоящее время для характеристики воспаления при ИВРЗ привлекает внимание определение концентрации КП в биологических жидкостях – так называемого циркулирующего или сывороточного (с) КП, увеличение концентрации которого может быть в большей степени связано с локальным (in situ), чем с системным, синтезом КП. В нарративном обзоре суммированы данные, касающиеся клинического значения определения сКП при ревматоидном артрите и других ИВРЗ как нового биомаркера активности воспаления. Представлены предварительные рекомендации, касающиеся показаний к определению сКП при ИВРЗ.
Об авторах
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Конфликт интересов:
Россия
Насонов Евгений Львович
115522, Москва, Каширское шоссе, 34а
Конфликт интересов:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
А. С. Авдеева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Конфликт интересов:
Россия
115522, Москва, Каширское шоссе, 34а
Конфликт интересов:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
А. А. Баранов
ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России
Россия
Конфликт интересов:
Россия
150000, Ярославль, ул. Революционная, 5
Конфликт интересов:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
М. Ю. Самсонов
АО «Р-ФАРМ»
Россия
Конфликт интересов:
Россия
119421, Москва, Ленинский просп., 111
Конфликт интересов:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Список литературы
1. Насонов ЕЛ, Баранов АА, Авдеева АС, Левшин НЮ, Лапкина НА, Абайтова НЕ, и др. Лабораторная диагностика иммуновоспалительных ревматических заболеваний. В: Долгов ВВ, Годков МА, Вавилова ТВ (ред.). Клиническая лабораторная диагностика. Национальное руководство. М.:ГЭОТАРМедиа;2025:557-602.
2. Colina M, Campana G. Precision medicine in rheumatology: The role of biomarkers in diagnosis and treatment optimization. J Clin Med. 2025;14(5):1735. doi: 10.3390/jcm14051735
3. Avouac J, Kay J, Choy E. Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: Potentials and challenges. Semin Arthritis Rheum. 2025;73:152740. doi: 10.1016/j.semarthrit.2025.152740
4. Sahin D, Di Matteo A, Emery P. Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review. Ann Clin Biochem. 2025;62(1):3-21. doi: 10.1177/00045632241285843
5. Насонов ЕЛ. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4):397-420. doi: 10.47360/1995-4484-2023-397-420
6. Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;70(2):169-182. doi: 10.15690/vramn.v70i2.1310
7. Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9
8. Mohan C, Assassi S. Biomarkers in rheumatic diseases: How can they facilitate diagnosis and assessment of disease activity? BMJ. 2015;351:h5079. doi: 10.1136/bmj.h5079
9. Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Berardicurti O, Bombardieri M, et al. Guidelines for biomarkers in autoimmune rheumatic diseases – evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003
10. Авдеева АС. Клиническое значение кальпротектина при ревматических заболеваниях. Научно-практическая ревматология. 2018;56(4):494-499. doi: 10.14412/1995-4484-2018-494-499
11. Romand X, Bernardy C, Nguyen MVC, Courtier A, Trocme C, Clapasson M, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019;86(6):691-698. doi: 10.1016/j.jbspin.2019.01.003
12. Carnazzo V, Redi S, Basile V, Natali P, Gulli F, Equitani F, et al. Calprotectin: Two sides of the same coin. Rheumatology (Oxford). 2024;63(1):26-33. doi: 10.1093/rheumatology/kead405
13. Manfredi M, Van Hoovels L, Benucci M, De Luca R, Coccia C, Bernardini P, et al. Circulating calprotectin (cCLP) in autoimmune diseases. Autoimmun Rev. 2023;22(5):103295. doi: 10.1016/j.autrev.2023.103295
14. Inciarte-Mundo J, Frade-Sosa B, Sanmartí R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front Immunol. 2022;13:1001025. doi: 10.3389/fimmu.2022.1001025
15. Wu YY, Li XF, Wu S, Niu XN, Yin SQ, Huang C, et al. Role of the S100 protein family in rheumatoid arthritis. Arthritis Res Ther. 2022;24(1):35. doi: 10.1186/s13075-022-02727-8
16. Wang X, Luo Y, Zhou Q, Ma J. The roles of S100A8/A9 and S100A12 in autoimmune diseases: Mechanisms, biomarkers, and therapeutic potential. Autoimmun Rev. 2025 Aug 26:103920. doi: 10.1016/j.autrev.2025.103920
17. Насонов ЕЛ, Авдеева АС, Решетняк ТМ, Алексанкин АП, Рубцов ЮП. Роль нетоза в патогенезе иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2023;61(5):513-530. doi: 10.47360/1995-4484-2023-513-530
18. Wang W, Cao W, Zhang S, Chen D, Liu L. The role of calprotectin in the diagnosis and treatment of inflammatory bowel disease. Int J Mol Sci. 2025;26(5):1996. doi: 10.3390/ijms26051996
19. Massa B, Mylemans M, Cruessen BV, Infantino M, Bossuyt X, Van Hoovels L, et al. Circulating calprotectin in rheumatoid arthritis: Unravelling the impact of (pre-)analytical confounders on meta-analysis results. J Lab Pres Med. 2024;(9):13.
20. Nevejan L, Mylemans M, Vander Cruyssen B, Stubbe M, Van Den Bremt S, Hofman L, et al. Pre-analytical recommendations and reference values for circulating calprotectin are sample type and assay dependent. Clin Chem Lab Med. 2021;60(2):e57- e60. doi: 10.1515/cclm-2021-0998
21. Mylemans M, Nevejan L, Van Den Bremt S, Stubbe M, Cruyssen BV, Moulakakis C, et al. Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample type. Clin Chim Acta. 2021;517:149-155. doi: 10.1016/j.cca.2021.02.022
22. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi: 10.1002/art.27584
23. Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, et al. The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. Front Med (Lausanne). 2018;5:185. doi: 10.3389/fmed.2018.00185
24. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: Acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014;16(1):R40. doi: 10.1186/ar4469
25. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%- 45% of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from Finland and the United States. J Rheumatol. 2009;36(7):1387-1390. doi: 10.3899/jrheum.080770
26. Mouliou DS. C-reactive protein: Pathophysiology, diagnosis, false test results and a novel diagnostic algorithm for clinicians. Diseases. 2023;11(4):132. doi: 10.3390/diseases11040132
27. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi: 10.1101/cshperspect.a016295
28. Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219-229. doi: 10.1016/j.semarthrit.2020.11.005
29. Bradford CM, McDonnell T, Raj D, Robinson GA, Cole A, Ramakrishnan S, et al. Characterization of a subset of patients with rheumatoid arthritis for whom current management strategies are inadequate. ACR Open Rheumatol. 2019;1(3):145-155. doi: 10.1002/acr2.1021
30. Lewis MJ, Çubuk C, Surace AEA, Sciacca E, Lau R, Goldmann K, et al.; STRAP collaborative group. Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis. Nat Commun. 2025;16(1):5374. doi: 10.1038/s41467-025-60987-9
31. Rivellese F, Pontarini E, Fossati-Jimack L, Moura RA, Romão VC, Fonseca JE, et al.; Pathobiology of Early Arthritis Cohort (PEAC) investigators. Comparative Analysis of circulating and synovial immune cells in early untreated rheumatoid arthritis and their relationship with molecular pathology and disease outcomes. Arthritis Rheumatol. 2025 Apr 27. doi: 10.1002/art.43194
32. Baillet A, Trocmé C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford). 2010;49(4):671-682. doi: 10.1093/rheumatology/kep452
33. Kang KY, Woo JW, Park SH. S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis. Korean J Intern Med. 2014;29(1):12-19. doi: 10.3904/kjim.2014.29.1.12
34. Brun JG, Haga HJ, Bøe E, Kallay I, Lekven C, Berntzen HB, et al. Calprotectin in patients with rheumatoid arthritis: Relation to clinical and laboratory variables of disease activity. J Rheumatol. 1992;19(6):859-862.
35. de Seny D, Fillet M, Ribbens C, Marée R, Meuwis MA, Lutteri L, et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem. 2008;54(6):1066-1075. doi: 10.1373/clinchem.2007.099549
36. García-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, et al. Calprotectin in rheumatoid arthritis: Association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther. 2013;17(1):49-56. doi: 10.1007/s40291-013-0016-9
37. Hammer HB, Odegard S, Fagerhol MK, Landewé R, van der Heijde D, Uhlig T, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66(8):1093-1097. doi: 10.1136/ard.2006.064741
38. Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11(2):R39. doi: 10.1186/ar2645
39. Hammer HB, Ødegård S, Syversen SW, Landewé R, van der Heijde D, Uhlig T, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):150-154. doi: 10.1136/ard.2008.103739
40. Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, Cañete JD, Cabrera-Villalba SR, Ramirez J, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford). 2015;54(12):2239-2243. doi: 10.1093/rheumatology/kev251
41. Andrés Cerezo L, Mann H, Pecha O, Pleštilová L, Pavelka K, Vencovský J, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R122. doi: 10.1186/ar3426
42. Jonsson MK, Sundlisæter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, et al. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann Rheum Dis. 2017;76(12):2031-2037. doi: 10.1136/annrheumdis-2017-211695
43. Bach M, Moon J, Moore R, Pan T, Nelson JL, Lood C. A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis Rheumatol. 2020;72(1):47-56. doi: 10.1002/art.41062
44. Wang Y, Liang Y. Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein. Int J Clin Exp Pathol. 2019;12(3):1009-1014.
45. Torgutalp M, Yayla ME, Eroglu DS, Dincer ABK, Yurteri EU, Okatan IE, et al. Serum calprotectin is indicating clinical and ultrasonographic disease activity in rheumatoid arthritis, even with normal C-reactive protein levels. Mediterr J Rheumatol. 2021;32(1):56-65. doi: 10.31138/mjr.32.1.56
46. Inciarte-Mundo J, Victoria Hernández M, Ruiz-Esquide V, Raquel Cabrera-Villalba S, Ramirez J, Cuervo A, et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken). 2016;68(7):899-906. doi: 10.1002/acr.22795
47. Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: A 1-year prospective cohort study. Arthritis Res Ther. 2018;20(1):275. doi: 10.1186/s13075-018-1764-z
48. Sakellariou G, Lombardi G, Vitolo B, Gomarasca M, Faraldi M, Caporali R, et al. Serum calprotectin as a marker of ultrasounddetected synovitis in early psoriatic and rheumatoid arthritis: Results from a cross-sectional retrospective study. Clin Exp Rheumatol. 2019;37(3):429-436.
49. Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, et al. Serum calprotectin (S100A8/9): An independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):252. doi: 10.1186/s13075-015-0764-5
50. Hurnakova J, Hulejova H, Zavada J, Hanova P, Komarc M, Mann H, et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS One. 2017;12(8):e0183420. doi: 10.1371/journal.pone.0183420
51. Bernardy C, Lejeune S, Courtier A, Wendling D, Berenbaum F, Nguyen MVC, et al. Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort. Joint Bone Spine. 2020;87(1):99-100. doi: 10.1016/j.jbspin.2019.07.001
52. Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923
53. Smith SL, Alexander S, Nair N, Viatte S, Eyre S, Hyrich KL, et al. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis. Ann Rheum Dis. 2023;82(5):611-620. doi: 10.1136/ard-2022-222519
54. Sejersen K, Weitoft T, Knight A, Lysholm J, Larsson A, Rönnelid J. Serum calprotectin correlates stronger with inflammation and disease activity in ACPA positive than ACPA negative rheumatoid arthritis. Rheumatology (Oxford). 2025;64(1):126-132. doi: 10.1093/rheumatology/kead641
55. Frade-Sosa B, Ponce A, Inciarte-Mundo J, Morlà R, RuizEsquide V, Macías L, et al. Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114105. doi: 10.1177/1759720X221114105
56. Frade-Sosa B, Ponce A, Ruiz-Ortiz E, De Moner N, Gómara MJ, Azuaga AB, et al. Neutrophilic activity biomarkers (plasma neutrophil extracellular traps and calprotectin) in established patients with rheumatoid arthritis receiving biological or JAK inhibitors: A clinical and ultrasonographic study. Rheumatol Ther. 2024;11(3):501-521. doi: 10.1007/s40744-024-00650-9
57. Nordal HH, Fagerhol MK, Halse AK, Hammer HB. Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis. Scand J Clin Lab Invest. 2018;78(1-2):102-108. doi: 10.1080/00365513.2017.1419371
58. Bettner LF, Peterson RA, Bergstedt DT, Kelmenson LB, Demoruelle MK, Mikuls TR, et al. Combinations of anticyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years. ACR Open Rheumatol. 2021;3(10):684-689. doi: 10.1002/acr2.11309
59. Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18(1):160. doi: 10.1186/s13075-016-1032-z
60. Stevens D, Sundbakk L, Kazemi A, Heiberg M, Sokka-Isler T, Gudbjornsson B, et al. Plasma calprotectin assessed in multiple biological treatment strategies for early rheumatoid arthritis over 48 weeks. Arthritis Rheumatol. 2024;76(Suppl 9). https://acrabstracts.org/abstract/plasma-calprotectin-assessed-in-multiple-biological-treatment-strategies-for-early-rheumatoid-arthritis-over-48-weeks
61. Авдеева АС, Черкасова МВ, Насонов ЕЛ. Динамика уровня кальпротектина у пациентов с ревматоидным артритом на фоне терапии биоаналогом ритуксимаба (Ацеллбия «Биокад»). Научно-практическая ревматология. 2021;59(4): 401-405. doi: 10.47360/1995-4484-2021-401-405
62. Zeng J, Liu X, Liu J, Wu P, Yang L. Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: A meta-analysis. Biomark Med. 2022;16(17):1239-1249. doi: 10.2217/bmm-2022-0216
63. Bae SC, Lee YH. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis. Postgrad Med. 2017;129(5):531-537. doi: 10.1080/00325481.2017.1319729
64. Massa B, Mylemans M, Vander Cruyssen B, Infantino M, Bossuyt X, Van Hoovels L. Circulating calprotectin in rheumatoid arthritis: Unravelling the impact of (pre-)analytical confounders on meta-analysis results. J Lab Precis Med. 2024;9:13. doi: 10.21037/jlpm-23-79
65. Low A, Lim F, Ma M. A systematic review looking at the relationship between serum calprotectin and ultrasound parameters in rheumatoid arthritis. Arthritis Rheumatol. 2021;73(Suppl 9): https://acrabstracts.org/abstract/a-systematic-review-looking-at-the-relationshipbetween-serum-calprotectin-and-ultrasound-parameters-in-rheumatoid-arthritis/
66. Nordal HH, Brokstad KA, Solheim M, Halse AK, Kvien TK, Hammer HB. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: Results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):3. doi: 10.1186/s13075-016-1201-0
67. Tweehuysen L, den Broeder N, van Herwaarden N, Joosten LAB, van Lent PL, Vogl T, et al. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering antiTNF treatment in patients with rheumatoid arthritis. RMD Open. 2018;4(1):e000654. doi: 10.1136/rmdopen-2018-000654
68. Andres Cerezo L, Mann H, Pecha O, Plestilova L, Pavelka K, Vencovsky J, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R122.
69. Kuley R, Duvvuri B, Hasnain S, Dow ER, Koch AE, Higgs RE, et al. Neutrophil activation markers and rheumatoid arthritis Treatment response to the JAK1/2 inhibitor baricitinib. Arthritis Rheumatol. 2025;77(4):395-404. doi: 10.1002/art.43042
70. Frade-Sosa B, Ponce A, Ruiz-Esquide V, García-Yébenes MJ, Morlá R, Sapena N, et al. High sensitivity C reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or JAK inhibitors: A clinical and ultrasonographic study. Diagnostics (Basel). 2022;12(1):182. doi: 10.3390/diagnostics12010182
71. Gernert M, Schmalzing M, Tony HP, Strunz PP, Schwaneck EC, Fröhlich M. Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy. Arthritis Res Ther. 2022;24(1):200. doi: 10.1186/s13075-022-02887-7
72. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43-52. doi: 10.1002/art.27740
73. Asai S, Takahashi N, Kobayakawa T, Kaneko A, Watanabe T, Kato T, et al. Comparison of the effects of baricitinib and tocili zumab on disease activity in patients with rheumatoid arthritis: A propensity score matching analysis. Clin Rheumatol. 2021;(8):3143-3151. doi: 10.1007/s10067-021-05815-3
74. Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C. Brief report: Remission rates with tofacitinib treatment in rheumatoid arthritis: A comparison of various remission criteria. Arthritis Rheumatol. 2017;69(4):728-734. doi: 10.1002/art.39996
75. Naredo E, Rodrigez M, Campos C, Rodríguez-Heredia JM, Medina JA, Giner E, et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Athritis Rheum. 2008;59:515-522. doi: 10.1002/art.23529
76. Алексеева ОГ. Ультразвуковое исследование суставов при ревматоидном артрите: патогенетическая обоснованность, возможности использования в диагностике, оценке эффективности терапии и прогнозировании исходов. Научнопрактическая ревматология. 2018;56(1):82-92. doi: 10.14412/1995-4484-2018-82-92
77. Ruscitti P, Cantarini L, Nigrovic PA, McGonagle D, Giacomelli R. Recent advances and evolving concepts in Still’s disease. Nat Rev Rheumatol. 2024;20(2):116-132. doi: 10.1038/s41584-023-01065-6
78. Насонов ЕЛ, Файст Е. Болезнь Стилла взрослых: новые горизонты. Научно-практическая ревматология. 2021;59(6):645- 665. doi: 10.47360/1995-4484-2021-643-663
79. De Matteis A, Bindoli S, De Benedetti F, Carmona L, Fautrel B, Mitrovic S. Systemic juvenile idiopathic arthritis and adult-onset Still’s disease are the same disease: Evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease. Ann Rheum Dis. 2024;83(12):1748-1761. doi: 10.1136/ard-2024-225853
80. Codes-Méndez H, Magallares-López B, Park HS, Mariscal A, Juárez C, Boronat S, et al. Diagnostic accuracy of serum calprotectin measured by CLIA and EIA in juvenile idiopathic arthritis: A proof-of-concept study. Front Pediatr. 2024;12:1422916. doi: 10.3389/fped.2024.1422916
81. d’Angelo DM, Attanasi M, Di Donato G, Lapergola G, Flacco M, Chiarelli F, et al. The role of serum calprotectin in defining disease outcomes in non-systemic juvenile idiopathic arthritis: A pilot study. Int J Mol Sci. 2023;24(2):1671. doi: 10.3390/ijms24021671
82. Romano M, Gerloni V, De Lucia O, Piskin D, Giani T, Gattinara M, et al. Serum calprotectin (S100A8/9), clinical and ultrasound assessment in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2021;39(5):1132-1140. doi: 10.55563/clinexprheumatol/5tckci
83. Aljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, et al. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: A retrospective analysis. Pediatr Rheumatol Online J. 2020;18(1):7. doi: 10.1186/s12969-020-0398-2
84. Barendregt AM, Veldkamp SR, Hissink Muller PCE, van de Geer A, Aarts C, van Gulik EC, et al. MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(9):2392-2401. doi: 10.1093/rheumatology/kez590
85. Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, et al. Serum S100A8/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis: Relationship to maintenance of clinically inactive disease during anti-tumor necrosis factor therapy and occurrence of disease flare after discontinuation of therapy. Arthritis Rheumatol. 2019;71(3):451-459. doi: 10.1002/art.40727
86. La C, Lê PQ, Ferster A, Goffin L, Spruyt D, Lauwerys B, et al. Serum calprotectin (S100A8/A9): A promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. RMD Open. 2021;7(2):e001646. doi: 10.1136/rmdopen-2021-001646
87. Boyko Y, Ivanova V, Vakaruk M, Kozina T, Shevchenko N, Vaizer N, et al. Blood calprotectin in children with juvenile idiopathic arthritis: Relationship to flare development after discontinuation of treatment. Reumatologia. 2020;58(4):202-207. doi: 10.5114/reum.2020.98431
88. Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17(1):200. doi: 10.1186/s13075-015-0723-1
89. Brunner HI, Schulert GS, Sproles A, Thornton S, Cornejo GV, Antón J, et al. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Res Ther. 2024;26(1):125. doi: 10.1186/s13075-024-03347-0
90. Keskitalo PL, Kangas SM, Sard S, Pokka T, Glumoff V, Kulmala P, et al. Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in realworld setting in a single center. Pediatr Rheumatol Online J. 2022;20(1):42. doi: 10.1186/s12969-022-00701-x
91. Sharma TK, Saxena S, Arora P, Sharma AK. S100A12 protein levels in juvenile idiopathic arthritis (JIA): A systematic review and meta-analysis. Clin Lab. 2025;71(5). doi: 10.7754/Clin.Lab.2024.241041
92. d’Angelo DM, Attanasi M, Di Donato G, Lapergola G, Cannataro G, Flacco M, et al. Serum calprotectin and joint ultrasound in the definition of disease relapse in non-systemic juvenile idiopathic arthritis: A prospective longitudinal study. Clin Exp Rheumatol. 2024;42(1):185-193. doi: 10.55563/clinexprheumatol/qumh2o
93. Foell D, Saers M, Park C, Brix N, Glerup M, Kessel C, et al. A novel serum calprotectin (MRP8/14) particle-enhanced immuno-turbidimetric assay (sCAL turbo) helps to differentiate systemic juvenile idiopathic arthritis from other diseases in routine clinical laboratory settings. Mol Cell Pediatr. 2023;10(1):14. doi: 10.1186/s40348-023-00168-0
94. Park C, Miranda-Garcia M, Berendes R, Horneff G, KuemmerleDeschner J, Ganser G, et al. MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology (Oxford). 2022;61(7):3082- 3092. doi: 10.1093/rheumatology/keab729
95. Breda L, La Bella S, Di Ludovico A. Biomarkers in juvenile idiopathic arthritis: Towards precision diagnosis and personalized therapy? Curr Opin Rheumatol. 2025;37(5):308-315. doi: 10.1097/BOR.0000000000001109
96. Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J, et al. Serum calprotectin – a promising diagnostic marker for adult-onset Still’s disease. Clin Rheumatol. 2016;35(1):73-79. doi: 10.1007/s10067-015-3108-6
97. Jung SY, Park YB, Ha YJ, Lee KH, Lee SK. Serum calprotectin as a marker for disease activity and severity in adult-onset Still’s disease. J Rheumatol. 2010;37(5):1029-1034. doi: 10.3899/jrheum.091120
98. Altobelli E, Angeletti PM, Petrocelli R, Lapergola G, Farello G, Cannataro G, et al. Serum calprotectin a potential biomarker in juvenile idiopathic arthritis: A meta-analysis. J Clin Med. 2021;10(21):4861. doi: 10.3390/jcm10214861
99. Pardeo M, Vastert SJ, De Benedetti F. It is about time: The first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2022;61(7):2724-2725. doi: 10.1093/rheumatology/keab948
100. Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Antón J, Belot A, et al. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Ann Rheum Dis. 2024;83(12):1614-1627. doi: 10.1136/ard-2024-225851
101. Hinze CH, Foell D, Kessel C. Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2023;19(12):778-789. doi: 10.1038/s41584-023-01042-z
102. Shen Y, Jia J, Teng J, Yang C, Hu Q. Advancing personalised precision treatment for Still’s disease based on molecular characteristics and disease progression. Lancet Rheumatol. 2025;7(2):e127-e140. doi: 10.1016/S2665-9913(24)00225-X.
103. Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014;62(6):880-884. doi: 10.1097/JIM.0000000000000095
104. Hu H, Du F, Zhang S, Zhang W. Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment. Mod Rheumatol. 2019;29(5):836-842. doi: 10.1080/14397595.2018.1519103
105. Gupta L, Bhattacharya S, Agarwal V, Aggarwal A. Elevated levels of serum MRP8/14 in ankylosing spondylitis: Associated with peripheral arthritis and active disease. Clin Rheumatol. 2016;35(12):3075-3079. doi: 10.1007/s10067-016-3448-x
106. Turina MC, Yeremenko N, Paramarta JE, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16(4):413. doi: 10.1186/s13075-014-0413-4
107. Rademacher J, Tietz LM, Le L, Hartl A, Hermann KA, Sieper J, et al. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology (Oxford). 2019;58(9):1556-1564. doi: 10.1093/rheumatology/kez025
108. Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, et al.; physicians of the Swiss Clinical Quality Management (SCQM) registry. Serum calprotectin: A promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020;22(1):105. doi: 10.1186/s13075-020-02190-3
109. Levitova A, Hulejova H, Spiritovic M, Pavelka K, Senolt L, Husakova M. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res Ther. 2016;18(1):275. doi: 10.1186/s13075-016-1180-1
110. Ma Y, Fan D, Xu S, Deng J, Gao X, Guan S, et al. Calprotectin in spondyloarthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106948. doi: 10.1016/j.intimp.2020.106948
111. Hammer HB, Kvien TK, Glennås A, Melby K. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol. 1995;13(1):59-64.
112. Sokolova MV, Simon D, Nas K, Zaiss MM, Luo Y, Zhao Y, et al. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther. 2020;22(1):26. doi: 10.1186/s13075-020-2111-8
113. Hansson C, Eriksson C, Alenius GM. S-calprotectin (S100A8/ S100A9): A potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res. 2014;2014:696415. doi: 10.1155/2014/696415
114. Li B, Li G, Song Z, Zhang Z. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: A 1-year longitudinal study. Rheumatol Ther. 2023;10(1):149-160. doi: 10.1007/s40744-022-00501-5
115. Aguilar-Zamora M, Montolio-Chiva L, Morena IDL, Lopez JM, Feced Olmos C, Orenes Vera AV, et al. Calprotectin in serum and synovial fluid as a biomarker in acute arthritis. Ann Rheum Dis. 2019;78:2021. doi: 10.1136/annrheumdis-2019-eular.7581
116. Cheng IT, Meng H, Li M, Li EK, Wong PC, Lee J, et al. Serum calprotectin level is independently associated with carotid plaque presence in patients with psoriatic arthritis. Front Med (Lausanne). 2022;9:932696. doi: 10.3389/fmed.2022.932696
117. Pepper RJ, Hamour S, Chavele KM, Todd SK, Rasmussen N, Flint S, et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. 2013;83(6):1150-1158. doi: 10.1038/ki.2013.2
118. Pepper RJ, Draibe JB, Caplin B, Fervenza FC, Hoffman GS, Kallenberg CG, et al.; RAVE-Immune Tolerance Network Research Group. Association of serum calprotectin (S100A8/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(1):185-193. doi: 10.1002/art.39814
119. Martinez Valenzuela L, Draibe J, Quero Ramos M, Fulladosa Oliveras X, Melilli E, Cruzado Garrit JM, et al. Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. PLoS One. 2018;13(10):e0205982. doi: 10.1371/journal.pone.0205982
120. Bai X, Xu PC, Chen T, Zhang HM, Wu SJ, Yang X, et al. The potential pathogenic roles of S100A8/ A9 and S100A12 in patients with MPO-ANCA-positive vasculitis. BMC Immunol. 2022;23(1):42. doi: 10.1186/s12865-022-00513-4
121. Romand X, Paclet MH, Chuong MV, Gaudin P, Pagnoux C, Guillevin L, et al. Serum calprotectin and renal function decline in ANCA-associated vasculitides: A post hoc analysis of MAINRITSAN trial. RMD Open. 2023;9(4):e003477. doi: 10.1136/rmdopen-2023-003477
122. Brown KL, Lubieniecka JM, Armaroli G, Kessel K, Gibson KM, Graham J, et al. S100A12 serum levels and PMN counts are elevated in childhood systemic vasculitides especially involving proteinase 3 specific anti-neutrophil cytoplasmic antibodies. Front Pediatr. 2018;6:341. doi: 10.3389/fped.2018.00341
123. Srsen S, Held M, Sestan M, Kifer N, Kozmar A, Supe Domic D, et al. Serum levels of S100A8/A9 as a biomarker of disease activity in patients with IgA vasculitis. Biomedicines. 2024;12(4):750. doi: 10.3390/biomedicines12040750
124. Zandstra J, van de Geer A, Tanck MWT, van Stijn-Bringas Dimitriades D, Aarts CEM, et al.; EUCLIDS Consortium, PERFORM Consortium and UK Kawasaki Disease Genetics Study Network. Biomarkers for the discrimination of acute Kawasaki disease from infections in childhood. Front Pediatr. 2020;8:355. doi: 10.3389/fped.2020.00355
125. Springer JM, Monach P, Cuthbertson D, Carette S, Khalidi NA, McAlear CA, et al. Serum S100 proteins as a marker of disease activity in large vessel vasculitis. J Clin Rheumatol. 2018;24(7):393-395. doi: 10.1097/RHU.0000000000000729
126. Saut A, Paclet MH, Trocmé C, Toussaint B, Bocquet A, Bouillet L, et al. Serum calprotectin is a marker of disease activity in giant cell arteritis. Autoimmun Rev. 2023;22(12):103469. doi: 10.1016/j.autrev.2023.103469
127. Kmetova K, Chong E, Somanathapura KN, Sugur K, Kluge L, Yalavarthi S, et al. Calprotectin, a mechanistically informed biomarker for clinically isolated aortitis. Arthritis Rheumatol. 2024;76(Suppl 9). URL: https://acrabstracts.org/abstract/calprotectin-a-mechanistically-informed-biomarker-for-clinically-isolated-aortitis/ (Accessed: 16th June 2025).
128. Nordal HH, Brun JG, Halse AK, Madland TM, Fagerhol MK, Jonsson R. Calprotectin (S100A8/A9), S100A12, and EDTAresistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome. Scand J Rheumatol. 2014;43(1):76-78. doi: 10.3109/03009742.2013.848930
129. Balarini GM, Zandonade E, Tanure L, Ferreira GA, Sardenberg WM, Serrano ÉV, et al. Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2016;34(6):1006-1012.
130. Jazzar AA, Shirlaw PJ, Carpenter GH, Challacombe SJ, Proctor GB. Salivary S100A8/A9 in Sjögren’s syndrome accompanied by lymphoma. J Oral Pathol Med. 2018;47(9):900-906. doi: 10.1111/jop.12763
131. Xu X, Wu WY, Tu WZ, Chu HY, Zhu XX, Liang MR, et al. Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities. Clin Rheumatol. 2013;32(10):1501-1510. doi: 10.1007/s10067-013-2305-4
132. van Bon L, Cossu M, Loof A, Gohar F, Wittkowski H, Vonk M, et al. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis. 2014;73(8):1585-1589. doi: 10.1136/annrheumdis-2013-205013
133. Ebrahimi B, Nazarinia M, Molayem M. Calprotectin, an available prognostic biomarker in systemic sclerosis: A systematic review. Clin Rheumatol. 2021;40(5):1709-1715. doi: 10.1007/s10067-020-05446-0
134. Pellicano C, Villa A, Carnazzo V, D’Ippolito G, Vinante I, Laterza F, et al. Serum calprotectin as a novel biomarker of disease severity and activity in systemic sclerosis patients. Int J Mol Sci. 2025;26(9):4290. doi: 10.3390/ijms26094290
135. Nistala K, Varsani H, Wittkowski H, Vogl T, Krol P, Shah V, et al. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Res Ther. 2013;15(5):R131. doi: 10.1186/ar4311
136. Lou Y, Zheng Y, Fan B, Zhang L, Zhu F, Wang X, et al. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease. BMC Pulm Med. 2020;20(1):196. doi: 10.1186/s12890-020-01226-3
137. Soyfoo MS, Roth J, Vogl T, Pochet R, Decaux G. Phagocytespecific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol. 2009;36(10):2190-2194.
138. Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(11):2048-2055. doi: 10.1093/rheumatology/ket263
139. Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Hughes GR. Calprotectin in patients with systemic lupus erythematosus: Relation to clinical and laboratory parameters of disease activity. Lupus. 1993;2(1):47-50. doi: 10.1177/096120339300200108
140. Tydén H, Lood C, Gullstrand B, Jönsen A, Ivars F, Leanderson T, et al. Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus. Lupus. 2017;26(2):139-149. doi: 10.1177/0961203316655208
141. Sumova B, Cerezo LA, Szczukova L, Nekvindova L, Uher M, Hulejova H, et al. Circulating S100 proteins effectively discriminate SLE patients from healthy controls: A cross-sectional study. Rheumatol Int. 2019;39(3):469-478. doi: 10.1007/s00296-018-4190-2
142. Wakiya R, Kameda T, Ueeda K, Nakashima S, Shimada H, Mansour MF, et al. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus. Lupus. 2019;28(7):826-833. doi: 10.1177/0961203319846391
143. Donohue SJ, Midgley A, Davies JC, Wright RD, Bruce I, Beresford MW, et al.; MRC MASTERPLANS Consortium; UK jSLE Cohort Study and Repository. Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). Clin Immunol. 2020;214:108375. doi: 10.1016/j.clim.2020.108375
144. Davies JC, Midgley A, Carlsson E, Donohue S, Bruce IN, Beresford MW, et al. Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open. 2020;6(2):e001257. doi: 10.1136/rmdopen-2020-001257
145. Kim JW, Jung JY, Lee SW, Baek WY, Kim HA, Suh CH. S100A8 in serum, urine, and saliva as a potential biomarker for systemic lupus erythematosus. Front Immunol. 2022;13:886209. doi: 10.3389/fimmu.2022.886209
146. Homa-Mlak I, Mazurek M, Majdan A, Mlak R, Majdan M, Mełecka-Massalska T. Serum calprotectin – a NET product – as a biomarker of disease activity in patients with systemic lupus erythematosus: A single-center case-control study from Poland. Med Sci Monit. 2022;28:e936534. doi: 10.12659/MSM.936534
147. Zervides KA, Jern A, Nystedt J, Gullstrand B, Nilsson PC, Sundgren PC, et al. Serum S100A8/A9 concentrations are associated with neuropsychiatric involvement in systemic lupus erythematosus: A cross-sectional study. BMC Rheumatol. 2022;6(1):38. doi: 10.1186/s41927-022-00268-w
148. Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, et al, Serum S100A8/ A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment. Front Immunol. 2024;14:1326751. doi: 10.3389/fimmu.2023.1326751
149. Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, et al. Association of elevated serum S100A8/A9 levels and cognitive impairment in systemic lupus erythematosus patients. Arthritis Care Res (Hoboken). 2025 May 19. doi: 10.1002/acr.25575
150. Kitagori K, Oku T, Wakabayashi M, Nakajima T, Nakashima R, Tian X, et al. Expression of S100A8 protein on B cells is associated with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2023;25(1):76. doi: 10.1186/s13075-023-03057-z
151. Zhao Y, Qi W, Huang C, Zhou Y, Wang Q, Tian X, et al. Serum calprotectin as a potential predictor of microvascular manifestations in patients with antiphospholipid syndrome. Rheumatol Ther. 2023;10(6):1769-1783. doi: 10.1007/s40744-023-00610-9
152. Hoy CK, Naveen Kumar SK, Navaz SA, Sugur K, Yalavarthi S, Sarosh C, et al. Calprotectin impairs platelet survival in patients with primary antiphospholipid syndrome. Arthritis Rheumatol. 2024;76(6):928-935. doi: 10.1002/art.42801
153. Sloan EE, Kmetova K, Naveen Kumar SK, Kluge L, Chong E, Hoy CK, et al. Non-criteria antiphospholipid antibodies and calprotectin as potential biomarkers in pediatric antiphospholipid syndrome. Clin Immunol. 2024;261:109926. doi: 10.1016/j.clim.2024.109926
154. Oktayoglu P, Mete N, Caglayan M, Bozkurt M, Bozan T, Em S, et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet’s disease and its association with disease activity and quality of life. Scand J Clin Lab Invest. 2015;75(2):106-112. doi: 10.3109/00365513.2014.984319
155. Omma A, Sandikci SC, Colak S, Tecer D, Yucel C, Ozbalkan Z. Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behçet’s disease. Postepy Dermatol Alergol. 2018;35(6):609-613. doi: 10.5114/pdia.2017.71269
156. Tezcan D, Onmaz DE, Sivrikaya A, Hakbilen S, Körez MK, Gülcemal S, et al. Assessment of serum neopterin and calprotectin as biomarkers for subclinical inflammation in patients with familial Mediterranean fever. Ir J Med Sci. 2023;192(4):2015-2022. doi: 10.1007/s11845-022-03173-w
157. Kilinc OC, Akdeniz YS, Taskin Z, Karabulut M, Kaya A, Bolayırlı IM, et al. Exploring S100A8/A9, neopterin, and MMP3 in familial Mediterranean fever. Clin Exp Immunol. 2024;218(1):93-100. doi: 10.1093/cei/uxae049
158. Polat MG, Omma A, Gokcen N, Kilinckaya MF, Ozkan Karaahmetoglu S. Role of serum calprotectin in identifying familial Mediterranean fever attacks. Ir J Med Sci. 2024;193(4):1901- 1909. doi: 10.1007/s11845-024-03659-9
159. Asan G, Derin ME, Doğan HO, Bayram M, Şahin M, Şahin A. Can calprotectin show subclinical inflammation in familial Mediterranean fever patients? J Korean Med Sci. 2020;35(10):e63. doi: 10.3346/jkms.2020.35.e63
160. Holzinger D, Nippe N, Vogl T, Marketon K, Mysore V, Weinhage T, et al. Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout. Arthritis Rheumatol. 2014;66(5):1327-1339. doi: 10.1002/art.38369
161. Vedder D, Gerritsen M, Nurmohamed MT, van Vollenhoven RF, Lood C. A neutrophil signature is strongly associated with increased cardiovascular risk in gout. Rheumatology (Oxford). 2021;60(6):2783-2790. doi: 10.1093/rheumatology/keaa712
162. Safa A, Bagherifard A, Hadi Al-Baseesee H, Amini Kadijani A, Yahyazadeh H, et al. Serum calprotectin as a blood-based biomarker for monitoring knee osteoarthritis at early but not late stages. Cartilage. 2021;13(Suppl 1):1566S-1571S. doi: 10.1177/1947603520961161
163. Frade-Sosa B, Chacur CA, Augé JM, Ponce A, Sarmiento-Monroy JC, Azuaga AB, et al. Calprotectin in patients with rheumatic immunomediated adverse effects induced by checkpoints inhibitors. Cancers (Basel). 2023;15(11):2984. doi: 10.3390/cancers15112984
164. Kaya T, Yaylacı S, Nalbant A, Yıldırım İ, Kocayiğit H, Çokluk E, et al. Serum calprotectin as a novel biomarker for severity of COVID-19 disease. Ir J Med Sci. 2022;191(1):59-64. doi: 10.1007/s11845-021-02565-8
165. Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating calprotectin as a biomarker of COVID-19 severity. Expert Rev Clin Immunol. 2021;17(5):431-443. doi: 10.1080/1744666X.2021.1905526
166. Zhang H, Zhang Q, Liu K, Yuan Z, Xu X, Dong J. Elevated level of circulating calprotectin correlates with severity and high mortality in patients with COVID-19. Immun Inflamm Dis. 2024;12(3):e1212. doi: 10.1002/iid3.1212
167. Udeh R, Advani S, de Guadiana Romualdo LG, Dolja-Gore X. Calprotectin, an emerging biomarker of interest in COVID-19: A systematic review and meta-analysis. J Clin Med. 2021;10(4):775. doi: 10.3390/jcm10040775
168. Machahua C, Guler SA, Horn MP, Planas-Cerezales L, MontesWorboys A, Geiser TK, et al. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: A crosssectional study in two independent cohorts. BMJ Open Respir Res. 2021;8(1):e000827. doi: 10.1136/bmjresp-2020-000827
169. Kotsiou OS, Papagiannis D, Papadopoulou R, Gourgoulianis KI. Calprotectin in lung diseases. Int J Mol Sci. 2021;22(4):1706. doi: 10.3390/ijms22041706
170. Zuo Y, Naveen Kumar SK, Navaz S, Liang W, Sugur K, Kmetova K, et al. Epidemiological and translational study of calprotectin and atherosclerotic cardiovascular disease. JAMA Cardiol. 2025;10(7):718-727. doi: 10.1001/jamacardio.2025.0945
171. Saenz-Pipaon G, Ravassa S, Larsen KL, Martinez-Aguilar E, Orbe J, Rodriguez JA, et al. Lipocalin-2 and calprotectin potential prognosis biomarkers in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2022;63(4):648-656. doi: 10.1016/j.ejvs.2022.01.012
172. Chen F, He Z, Wang C, Si J, Chen Z, Guo Y. Advances in the study of S100A9 in cardiovascular diseases. Cell Prolif. 2024;57(8):e13636. doi: 10.1111/cpr.13636
173. Plana E, Oto J, Herranz R, Medina P, Cana F, Miralles M. Calprotectin as a new inflammatory marker of abdominal aortic aneurysm: A pilot study. Vasc Med. 202;29(2):189-199. doi: 10.1177/1358863X241231494
174. Haybar H, Ramezani B, Assareh AR, Kardooni A, Azizidoost S. Calprotectin correlates with reduced level of LVEF and occurrence of cardiac arrhythmia in STEMI patients. Adv Biomed Res. 2024;13:90. doi: 10.4103/abr.abr_438_23
175. Amaya-Garrido A, Brunet M, Buffin-Meyer B, Piedrafita A, Grzesiak L, Agbegbo E, et al. Calprotectin is a contributor to and potential therapeutic target for vascular calcification in chronic kidney disease. Sci Transl Med. 2023;15(712):eabn5939. doi: 10.1126/scitranslmed.abn5939
176. Reshadmanesh T, Behnoush AH, Farajollahi M, Khalaji A, Ghondaghsaz E, Ahangar H. Circulating levels of calprotectin as a biomarker in patients with coronary artery disease: A systematic review and meta-analysis. Clin Cardiol. 2024;47(7):e24315. doi: 10.1002/clc.24315
177. Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2024;21(11):780-807. doi: 10.1038/s41569-024-01045-7
178. Sparks R, Rachmaninoff N, Lau WW, Hirsch DC, Bansal N, Martins AJ, et al. A unified metric of human immune health. Nat Med. 2024;30(9):2461-2472. doi: 10.1038/s41591-024-03092-6
Рецензия
Для цитирования:
Насонов Е.Л., Авдеева А.С., Баранов А.А., Самсонов М.Ю. Сывороточный кальпротектин при иммуновоспалительных ревматических заболеваниях: новый биомаркер воспаления. Научно-практическая ревматология. 2025;63(5):432-442. https://doi.org/10.47360/1995-4484-2025-432-442
For citation:
Nasonov E.L., Avdeeva A.S., Baranov A.A., Samsonov M.Yu. Serum calprotectin in immune-mediated inflammatory rheumatic diseases: a new biomarker of inflammation. Rheumatology Science and Practice. 2025;63(5):432-442. (In Russ.) https://doi.org/10.47360/1995-4484-2025-432-442
Просмотров:
11
Послать статью по эл. почте 